四環醫藥(00460.HK):兩款非PVC粉液雙室袋產品獲納入2022年國家醫保目錄
格隆匯1月26日丨四環醫藥(00460.HK)發佈公吿,根據國家醫療保障局、中國人力資源和社會保障部正式發佈的《關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄(2022年)〉的通知》(“2022年國家醫保目錄”),集團與其聯營公司北京鋭業製藥有限公司共同開發的兩款首家及獨家產品,“非PVC粉液雙室袋注射用頭孢他啶╱氯化鈉注射液”和“非PVC粉液雙室袋注射用頭孢呋辛鈉╱氯化鈉注射液”(“非PVC粉液雙室袋產品”),獲納入2022年國家醫保目錄。
公吿表示,抗感染領域一直是集團重點佈局領域,本次兩款非PVC粉液雙室袋產品獲納入2022年國家醫保目錄,同時作為國內首家、國產獨家劑型,預計會對現有產品形成一定的替代,並對今後擴大銷售規模和提升市場佔有率,以及公司的經營業績將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.